Development and validation of a stability indicating RP-LC method for determination of imatinib mesylate

被引:19
作者
Bende, Girish [1 ]
Kollipara, Sivacharan [1 ]
Kolachina, Venugopal [1 ]
Saham, Ranendra [1 ]
机构
[1] Birbal Inst Technol & Sci, Formulat Dev & Pharmacokinet Lab, Pharma Grp, Pilani 333031, Rajasthan, India
关键词
column liquid chromatography; microwave-assisted degradation; orthogonal separation; imatinib mesylate;
D O I
10.1365/s10337-007-0415-3
中图分类号
Q5 [生物化学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
A new, sensitive and stability indicating liquid chromatographic method has been developed for the determination of imatinib mesylate (IM). Efficient chromatographic separation was achieved using a C-18 column with simple mobile phase combination delivered in an isocratic mode and quantitation was carried out using ultraviolet detection. For the first time, a novel microwave assisted degradation procedure was employed for stress testing studies. In addition, orthogonal separation technique was applied to demonstrate selectivity of the proposed method. The method has demonstrated excellent linearity over the range of 25-1,600 ng mL(-1). Moreover, the method was found to be sensitive with a low limit of detection (3.35 ng mL(-1)) and limit of quantitation (10.16 ng mL(-1)). The method has shown good and consistent recoveries (99.35-100.69%) with low intra- and inter-day relative standard deviation (RSD) (< 2.5%). Experimental design confirmed that peak area was unaffected by small changes in critical factors, in robustness study. The validated method was successfully applied for determination of IM in pharmaceutical formulations.
引用
收藏
页码:859 / 866
页数:8
相关论文
共 17 条
[1]
[Anonymous], 1996, NOTE GUIDANCE VALIDA
[2]
Bolton S., 1997, PHARM STAT PRACTICAL, P216
[3]
Imatinib as a paradigm of targeted therapies [J].
Druker, BJ .
ADVANCES IN CANCER RESEARCH, VOL 91, 2004, 91 :1-+
[4]
Imatinib (Gleevec®, Glivec®) tumour tissue analysis by measurement of sediment and by liquid chromatography tandem mass spectrometry [J].
Guetens, G ;
Prenen, H ;
De Boeck, G ;
Highley, M ;
de Wever, I ;
van Oosterom, AT ;
de Bruijn, EA .
JOURNAL OF SEPARATION SCIENCE, 2006, 29 (03) :453-459
[5]
Hochhaus A., 2004, Annals of Hematology, V83, pS65
[6]
Reversed-phase liquid chromatography analysis of imatinib mesylate and impurity product in Glivec® capsules [J].
Ivanovic, D ;
Medenica, M ;
Jancic, B ;
Malenovic, A .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 800 (1-2) :253-258
[7]
Targeted therapies for the treatment of cancer [J].
Kim, JA .
AMERICAN JOURNAL OF SURGERY, 2003, 186 (03) :264-268
[8]
LEVITZKI A, 2002, ENCY CANC, P475
[9]
LEWIS GA, 1999, PHARM EXPT DESIGN, P79
[10]
Orthogonal separations for reversed-phase liquid chromatography [J].
Pellett, J ;
Lukulay, P ;
Mao, Y ;
Bowen, W ;
Reed, R ;
Ma, M ;
Munger, RC ;
Dolan, JW ;
Wrisley, L ;
Medwid, K ;
Toltl, NP ;
Chan, CC ;
Skibic, M ;
Biswas, K ;
Wells, KA ;
Snyder, LR .
JOURNAL OF CHROMATOGRAPHY A, 2006, 1101 (1-2) :122-135